US
US Gene Editing Market Industry Trends and Forecast to 2034: Segmented by (Technology, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $3.01 Bn.
Canada at 18.3% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$8.43 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.59 Bn | — | — |
| 2025 (base) | $3.01 Bn | +$414.7 Mn | — |
| 2026 (forecast) | $3.49 Bn | +$481.1 Mn | +16% |
| 2027 (forecast) | $4.05 Bn | +$558.1 Mn | +34.6% |
| 2028 (forecast) | $4.69 Bn | +$647.3 Mn | +56.1% |
| 2029 (forecast) | $5.44 Bn | +$750.9 Mn | +81.1% |
| 2030 (forecast) | $6.32 Bn | +$871.1 Mn | +110% |
| 2031 (forecast) | $7.33 Bn | +$1.01 Bn | +143.6% |
| 2032 (forecast) | $8.50 Bn | +$1.17 Bn | +182.6% |
| 2033 (forecast) | $9.86 Bn | +$1.36 Bn | +227.8% |
| 2034 (forecast) | $11.43 Bn | +$1.58 Bn | +280.3% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$3.01 Bn
Canada
$615.2 Mn
China
$546.4 Mn
Japan
$424.3 Mn
Germany
$296.6 Mn
France
$208.2 Mn
Brazil
$191.9 Mn
UK
$178.9 Mn
Italy
$179.8 Mn
Spain
$153.9 Mn
Ecuador
$150.2 Mn
Saudi Arabia
$149.7 Mn
Mexico
$131.4 Mn
India
$128.5 Mn
Australia
$96.8 Mn
Russia
$83.5 Mn
New Zealand
$83.5 Mn
South Africa
$53.6 Mn
UAE
$40.2 Mn
Egypt
$23.3 Mn
Philippines
$14.9 Mn
Hong Kong
$13.7 Mn
Malaysia
$11.8 Mn
Singapore
$10.3 Mn
Thailand
$9.2 Mn
Kenya
$5.2 Mn
Gene editing tools such as CRISPR, base editing and prime editing change DNA inside cells to fix or switch off faulty genes.
Key segments of the gene Editing market include technology (CRISPR-Cas9, Base Editing and Prime Editing) and application (Therapeutics, Research and Agriculture).
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Editing market.
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the gene Editing market.
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the gene Editing market. Payers are still working out how to pay for one-time cures.
The gene Editing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gene Editing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Gene Editing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
US · 1 shared keyword
US · 1 shared keyword
US
US
US
US
Digital Health · US
Healthcare Services · US
Healthcare Services · US
Medical Devices · US
Digital Health · US
Medical Devices · US